Here’s a comprehensive overview of Anlon Healthcare Limited IPO based on the most up-to-date information.
Established: Incorporated in 2013, based in Rajkot, Gujarat.
Business Focus: Manufacturing of pharmaceutical intermediates, APIs, nutraceutical APIs, personal care & veterinary APIs.
Product Portfolio: 65 commercial products, 28 in pilot stage, 49 in laboratory testing.
Regulatory Approvals: Holds DMFs from IN, EU, China (NMPA), Brazil (ANVISA), Japan (PMDA); additional filings underway.
Global Footprint: Serving over 15 countries, including markets like Italy, Germany, South Korea, China, Japan, Brazil, UK, UAE.
Manufacturing & Quality: ISO 9001:2015 certified; WHO-GMP certified; two manufacturing blocks; in-house labs and advanced equipment.
Promoters: Punitkumar R. Rasadia, Meet Atulkumar Vachhani, Mamata Punitkumar Rasadia.
IPO Dates
- Opening Date: August 26, 2025
- Closing Date: August 29, 2025
- Allotment Date: September 1, 2025
- Refund & Credit Date: September 2, 2025
- Listing Date: September 3, 2025
IPO Details
- Face Value: ₹10 per share
- Issue Type: Book-built IPO
- Issue Size: Approximately ₹121.03 crore, comprising about 1.33 crore equity shares
- Price Band: ₹86 to ₹91 per share
- Lot Size: 164 shares
- Minimum Investment (Retail): For one lot of 164 shares at cap price ₹91, approx. ₹14,924
- Listing At: NSE, BSE
- Share Holding Pre Issue: 3,98,51,500 shares
- Share Holding Post Issue: 5,31,51,500 shares
GMP of Anlon Healthcare Limited IPO
Here’s the latest update on the Grey Market Premium (GMP) for Anlon Healthcare Limited IPO based on reliable sources:
As of August 24, 2025, the GMP is reported to be ₹0, indicating no premium in the grey market. This implies that the estimated listing price aligns with the IPO’s upper price band (₹91), with no expected gain or loss over that price.
Summary Table
| Date | GMP (₹) | Estimated Listing Price | Notes |
|---|---|---|---|
| August 22, 2025 | — | — | No GMP movement tracked |
| August 24, 2025 | 0 | ₹91 | Grey market shows no premium |
Promoters of Anlon Healthcare Limited
Here’s what I found on the promoters of Anlon Healthcare Limited, along with their roles and backgrounds:
1. Punitkumar R. Rasadia
- Chairman and Managing Director of the company.
- A founding promoter, associated with Anlon Healthcare since inception.
- Holds a Master’s degree in Industrial Chemistry with over 11 years of experience in the pharmaceutical industry.
- Plays a key role in strategy, operations, and business growth.
2. Atulkumar Vachhani (Meet Atulkumar Vachhani)
- Works as the Whole-time Executive Director and is also a founding promoter.
- 11 years of experience in the pharmaceutical industry.
- Responsible for the administration, strategy, finance, and sales functions of the company.
- Involved in strategy formulation, operations management, and product innovation.
- Associated with the same related companies: Anlon Chemical Research Organization, Advintel Medicare Private Limited, and Anlon Lifescience Private Limited.
3. Mamata Punitkumar Rasadia
- Serves as a Non-Executive, Non-Independent Director.
- Became a promoter and director on July 15, 2024.
- Holds a Master of Science in Chemistry and a Diploma in Pharmacy, both from Saurashtra University.
Summary Table
| Promoter Name | Role / Title | Background & Responsibilities |
|---|---|---|
| Punitkumar R. Rasadia | Chairman & Managing Director | MS in Industrial Chemistry; 11+ years in pharma; leads strategy, operations, business growth |
| Atulkumar Vachhani | Whole-time Executive Director | 11+ years in pharma; handles admin, finance, ops, sales, strategy, product innovation |
| Mamata Punitkumar Rasadia | Non-Executive Non-Independent Director | MSc & Diploma in Pharmacy; joined July 2024 |
Anlon Healthcare Limited IPO Lot Size
Here’s the lot size details for the Anlon Healthcare Limited IPO, laid out in a clear table:
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
Anlon Healthcare Limited IPO Promoter Holding
Here’s the detailed information on the promoter holding of Anlon Healthcare Limited IPO, including both pre- and post-issue percentages, presented clearly.
| Descriptor | Promoter Holding |
|---|---|
| Pre-IPO (Pre-Issue) | 70.26 % |
| Post-IPO (Post-Issue) | 52.68 % |
- Pre-IPO promoter holding remains steady at 70.26 %, indicating their share in the company before the IPO.
- Post-IPO promoter holding is estimated at 52.68 %, reflecting dilution after the fresh issue of shares.
About Anlon Healthcare Limited
- Established: Incorporated in 2013, based in Rajkot, Gujarat.
- Business Focus: Manufacturing of pharmaceutical intermediates, APIs, nutraceutical APIs, personal care & veterinary APIs.
- Product Portfolio: 65 commercial products, 28 in pilot stage, 49 in laboratory testing.
- Specialization: Anlon Healthcare Limited is a research-intensive manufacturer of high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), operating out of Rajkot, India.
- Regulatory Compliance & Quality: The company adheres to stringent global standards such as FDA, PMDA, KFDA, cGMP, WHO-GMP, ensuring high-quality production.
- Innovation & Custom Manufacturing: It offers custom manufacturing services, including processes for complex compounds with purity levels exceeding industry norms.
Product Portfolio & R&D Capabilities
Product Range:
- 65 commercialized products
- 28 products in pilot stage
- 49 products under laboratory testing
Drug Master File (DMF) Filings & Approvals: It holds regulatory approvals from ANVISA (Brazil), NMPA (China), PMDA (Japan), and has filed DMFs across multiple geographies, including the EU, Russia, USA, and Spain
Key API: One of the few Indian manufacturers of loxoprofen sodium dihydrate, widely used in pain and inflammation treatments
Global Reach & Market Presence
- Export Footprint: Anlon exports to over 15 countries, including major markets like Germany, Italy, South Korea, China, Japan, Brazil, as well as regions in Latin America, MENA, Europe, and CIS.
- R&D Infrastructure: Operates four R&D labs, supported by a science team and advanced testing facilities.
Summary Table: Quick Snapshot
| Attribute | Detail |
|---|---|
| Headquarters | Rajkot, Gujarat, India |
| Founded | Incorporated in 2013 |
| Core Products | Pharma Intermediates & APIs |
| Regulatory Standards | FDA, PMDA, KFDA, cGMP, WHO-GMP, IP, BP, EP, JP, USP |
| Product Portfolio | 65 commercial, 28 pilot, 49 R&D |
| Global Exports | ~15+ countries across Europe, Asia, LATAM, MENA |
| IPO Objective | Raise ₹121 crore (facility expansion, debt, working capital) |
Anlon Healthcare Limited Financial Information
Here is a refined and structured overview of Anlon Healthcare Limited financial performance, complete with a detailed table summarizing key metrics across recent fiscal years:
| Period Ended | 31 Mar 2025 | Mar 31 2024 | 31 Mar 2023 |
| Assets | ₹181.30 Crore | ₹128.00 Crore | ₹111.55 Crore |
| Total Income | ₹120.46 Crore | ₹66.69 Crore | ₹113.12 Crore |
| Profit After Tax | ₹20.52 Crore | ₹9.66 Crore | ₹5.82 Crore |
| EBITDA | ₹32.38 Crore | ₹15.57 Crore | ₹12.66 Crore |
| Net Worth | ₹80.42 Crore | ₹21.03 Crore | ₹7.37 Crore |
| Reserves and Surplus | ₹40.57 Crore | ₹5.03 Crore | ₹-4.63 Crore |
| Total Borrowing | ₹58.35 Crore | ₹74.56 Crore | ₹66.39 Crore |
Key Performance Indicator (KPI)
Certainly! Here’s a clean and well-organized overview of the Key Performance Indicators (KPIs) for Anlon Healthcare Limited, based on the latest financial data reported in its IPO documents and filings.
| KPI | Values |
|---|---|
| ROE | 40.45% |
| ROCE | 21.93% |
| Debt/Equity | 0.73 |
| RoNW | 25.51% |
| PAT Margin | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
Strengths of Anlon Healthcare Limited IPO
Broad and High-Quality Product Portfolio
Anlon offers a wide array of APIs and intermediates, including niche compounds like loxoprofen sodium dihydrate, and serves various sectors such as nutraceuticals, personal care, and veterinary health. Validation from multiple DMF approvals (ANVISA, NMPA, PMDA) further reinforces its product credibility.
Experienced Promoter Team & Scalable Operations
The promoters have been steering the company since inception, demonstrating long-term commitment. Their strategic footprint includes a scalable operation supported by in-house R&D and quality assurance labs.
High Barriers to Entry & Robust Compliance
Long approval cycles, strict pharmacopeial standards, and regulatory certifications foster strong entry barriers. Anlon’s advanced quality control ecosystem deepens this moat.
Lean Balance Sheet with Strong Growth Trajectory
The company has executed a notable turnaround—boasting ~81% growth in revenue and ~66% growth in net profit from FY24 to FY25. Its debt-to-equity ratio has significantly declined to ~0.73x, signaling stronger financial health and operational leverage.
Strategic Use of IPO Proceeds
The funds from the IPO will be judiciously allocated toward facility expansion (₹30.7 Cr), debt repayments (₹5 Cr), working capital (~₹43 Cr), and general growth initiatives, emphasizing balanced corporate strategy.
Risks of Anlon Healthcare Limited IPO
Customer Concentration
A large chunk of revenue (~75–78%) comes from the top 10 customers. Losing any of these clients could substantially impact revenues and operational cash flows.
Geographic and Facility Concentration
Operations are centralized in a single Rajkot-based manufacturing facility, heightening exposure to localized disruptions—be it logistic, regulatory, or environmental.
Stringent Compliance Requirements
The company is subject to rigorous technical standards, inspections, and audits. Non-compliance could lead to cancellations of contracts or blocked orders, directly affecting credibility and revenues.
Operational Cash Flow Challenges
Operating cash flows have been negative for several recent periods—a concern despite improving profits, as it presses liquidity and working capital management.
Sector-Specific Dependency
Heavy reliance on the pharmaceutical sector makes Anlon vulnerable to industry-specific headwinds like regulatory shifts, raw material cost hikes, or competitive disruptions.
Summary Table
| Category | Highlights |
|---|---|
| Strengths | Wide product range, global approvals, experienced team, improving finances, regulated growth strategy |
| Risks | High customer and facility concentration, stringent regulatory compliance, negative cash flows, sector sensitivity, IPO uncertainty |
Final Thoughts
Anlon Healthcare’s IPO stands out with its strong fundamentals and growth potential. With a robust product mix and regulatory credibility, it addresses key factors investors value in pharma-focused firms.
However, the company must navigate dependencies on key customers, operational liquidity pressures, and compliance demands.
If you lean toward medium to long-term investing and expect continued strong execution and expansion, this could be a opportunity worth considering.
Anlon Healthcare Limited Contact Details
Here are the contact details for Anlon Healthcare Limited, including both their corporate (registered) office and manufacturing facility:
Anlon Healthcare Limited – Contact Information
Factory Address (Manufacturing Facility)
- Location: Survey No. 36/2, Near Bharudi Toll Plaza, Gondal Road NH27,
PO: Pipaliya (Sadak), Taluka Gondal, Rajkot, Gujarat, India - Phone: +91-70696 90081 / +91-70696 90082
- Email: info@anlonhealthcare.com
Registered (Corporate) Office
- Location: 101/102—Silver Coin Complex, Opp. Crystal Mall, Kalawad Road,
Rajkot 360005, Gujarat, India - Phone: +91-281-2561 340, +91-281-2562 538/39
- Email: info@anlonhealthcare.com
Investors’ Grievance / Company Secretary
- Contact Person: Ms. Amita Pragada, Company Secretary
- Office Address: Same as corporate office (Silver Coin Complex, Kalawad Road, Rajkot)
- Phone: +91-281-2562 538 / 39
- Email: cs@anloncro.com
Registrar & Share Transfer Agent (for IPO-related queries)
- Company: KFin Technologies Limited
- Address: Selenium Tower B, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032, Telangana, India
- Phone: +91-40-6716 2222
- Email: ahl.ipo@kfintech.com
Summary Table
| Category | Details |
|---|---|
| Factory Address | Survey No. 36/2, Near Bharudi Toll Plaza, Gondal Road NH27, PO Pipaliya (Sadak), Tal: Gondal, Rajkot, Gujarat |
| Factory Phone | +91-70696 90081 / +91-70696 90082 |
| Factory Email | info@anlonhealthcare.com |
| Registered Office | 101/102—Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot 360005 |
| Registered Office Phone | +91-281-2561 340, +91-281-2562 538/39 |
| Registered Office Email | info@anlonhealthcare.com |
| Investor Queries (CS) | Ms. Amita Pragada, Company Secretary +91-281-2562 538/39 cs@anloncro.com |
| IPO Registrar & Share Transfer Agent | KFin Technologies Limited, Hyderabad +91-40-6716 2222 ahl.ipo@kfintech.com |
Vikran Engineering Limited IPO 2025: Dates, Price & Review
Regaal Resources Limited IPO Details: Dates, Lot Size, Price & Review
Disclaimer: The content on this website is intended for informational purposes only and should not be interpreted as financial or investment advice. Engaging in stock market activities involves inherent risks, and outcomes can be unpredictable. While we strive to provide accurate and up-to-date information, we do not make any guarantees regarding the completeness or reliability of the content. Any investment decisions you make should be based on your own research and consultation with a qualified financial professional. We are not responsible for any financial gains or losses resulting from actions taken based on the information provided here. Always invest wisely and at your own risk.
